Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05063162




Registration number
NCT05063162
Ethics application status
Date submitted
21/09/2021
Date registered
30/09/2021
Date last updated
22/11/2024

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)
Secondary ID [1] 0 0
2021-000352-19
Secondary ID [2] 0 0
MOG001
Universal Trial Number (UTN)
Trial acronym
cosMOG
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD) 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Rozanolixizumab
Other interventions - Placebo

Experimental: Rozanolixizumab Arm - Participants randomized into this arm will receive rozanolixizumab at pre-specified timepoints.

Placebo comparator: Placebo Arm - Participants randomized into this arm will receive placebo at pre-specified timepoints to maintain the blinding.


Treatment: Drugs: Rozanolixizumab
* Pharmaceutical form: Solution for infusion
* Route of administration: subcutaneous infusion

Participants will receive pre-specified doses of rozanolixizumab.

Other interventions: Placebo
* Pharmaceutical form: Solution for infusion
* Route of administration: subcutaneous infusion

Participants will receive placebo.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
For Part A: Time from randomization to first independently centrally adjudicated relapse (TTFR) during the DB Treatment Period
Timepoint [1] 0 0
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks)
Primary outcome [2] 0 0
For Part B: Incidence of treatment-emergent adverse events (TEAEs) during OLE Treatment Period
Timepoint [2] 0 0
OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
Primary outcome [3] 0 0
For Part B: Incidence of treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of investigational medicinal product (IMP) during OLE Treatment Period
Timepoint [3] 0 0
OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
Secondary outcome [1] 0 0
For Part A: Change from Baseline in Low-Contrast Monocular Visual Acuity (Worst Affected Eye) measured by low-contrast Landolt C Broken Rings Chart at the EDB/EWD Visit
Timepoint [1] 0 0
From Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks)
Secondary outcome [2] 0 0
For Part A: Disability as assessed by Expanded Disability Status Scale (EDSS) scores at the EDB/EWD Visit (with confirmation at 3 months)
Timepoint [2] 0 0
Baseline (Week 1), EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks)
Secondary outcome [3] 0 0
For Part A: Number of MOG-AD related inpatient hospitalizations during the DB Treatment Period
Timepoint [3] 0 0
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks)
Secondary outcome [4] 0 0
For Part A: Incidence of treatment-emergent adverse events (TEAEs) during the DB Treatment Period
Timepoint [4] 0 0
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks)
Secondary outcome [5] 0 0
For Part B: Independently centrally adjudicated annualized relapse rate (ARR) during the DB and OLE Treatment Period
Timepoint [5] 0 0
Baseline (Week 1) to EOS/EWD Visit (up to OLE Week 52)

Eligibility
Key inclusion criteria
* Participant must be =18 to =89 years of age, at the time of signing the informed consent
* Confirmed diagnosis of MOG-AD consistent with published diagnostic criteria for MOG-AD
* Participant has history of relapsing MOG-AD with at least 1 documented relapse over the last 12 months and a documented positive serum MOG Ab test using a cell-based assay (CBA) within 6 months prior to randomization
* Participant must be clinically stable at the time of the Screening Visit and during the Screening Period
Minimum age
18 Years
Maximum age
89 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participant has been diagnosed with a neurological autoimmune disease (including multiple sclerosis (MS) and aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD)), or a systemic autoimmune disease that in the opinion of the investigator can interfere with the safety of the participant
* Participant has a clinically important active infection (including unresolved or not adequately treated infection) as assessed by the investigator, including participants with a serious infection within 6 weeks prior to the first dose of the investigational medicinal product (IMP)
* Participant has a current or medical history of primary immunodeficiency
* Participant tests positive for aquaporin-4 antibodies at Screening
* Participant has a serum total IgG level = 5.5g/L

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/02/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/07/2027
Actual
Sample size
Target
104
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Mog001 30022 - Melbourne
Recruitment hospital [2] 0 0
Mog001 30026 - Southport
Recruitment postcode(s) [1] 0 0
- Melbourne
Recruitment postcode(s) [2] 0 0
- Southport
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Utah
Country [14] 0 0
Belgium
State/province [14] 0 0
Edegem
Country [15] 0 0
Belgium
State/province [15] 0 0
Gent
Country [16] 0 0
Brazil
State/province [16] 0 0
Porto Alegre
Country [17] 0 0
Czechia
State/province [17] 0 0
Hradec Kralove
Country [18] 0 0
Czechia
State/province [18] 0 0
Prague 2
Country [19] 0 0
Czechia
State/province [19] 0 0
Teplice
Country [20] 0 0
France
State/province [20] 0 0
Bron Cedex
Country [21] 0 0
France
State/province [21] 0 0
Caen
Country [22] 0 0
France
State/province [22] 0 0
Marseille
Country [23] 0 0
France
State/province [23] 0 0
Montpellier
Country [24] 0 0
France
State/province [24] 0 0
Strasbourg
Country [25] 0 0
Germany
State/province [25] 0 0
Berlin
Country [26] 0 0
Germany
State/province [26] 0 0
Göttingen
Country [27] 0 0
Germany
State/province [27] 0 0
ULM
Country [28] 0 0
Italy
State/province [28] 0 0
Pavia
Country [29] 0 0
Italy
State/province [29] 0 0
Roma
Country [30] 0 0
Italy
State/province [30] 0 0
Verona
Country [31] 0 0
Japan
State/province [31] 0 0
Bunkyo-ku
Country [32] 0 0
Japan
State/province [32] 0 0
Chiba-shi
Country [33] 0 0
Japan
State/province [33] 0 0
Isehara
Country [34] 0 0
Japan
State/province [34] 0 0
Kodaira
Country [35] 0 0
Japan
State/province [35] 0 0
Koriyama
Country [36] 0 0
Japan
State/province [36] 0 0
Sendai
Country [37] 0 0
Japan
State/province [37] 0 0
Shinjuku-ku
Country [38] 0 0
Japan
State/province [38] 0 0
Suita
Country [39] 0 0
Korea, Republic of
State/province [39] 0 0
Goyang-si
Country [40] 0 0
Korea, Republic of
State/province [40] 0 0
Seoul
Country [41] 0 0
Mexico
State/province [41] 0 0
Ciudad de Mexico
Country [42] 0 0
Mexico
State/province [42] 0 0
Culiacán
Country [43] 0 0
Portugal
State/province [43] 0 0
Coimbra
Country [44] 0 0
Portugal
State/province [44] 0 0
Porto
Country [45] 0 0
Spain
State/province [45] 0 0
Barcelona
Country [46] 0 0
Spain
State/province [46] 0 0
Madrid
Country [47] 0 0
Spain
State/province [47] 0 0
Murcia
Country [48] 0 0
Spain
State/province [48] 0 0
Málaga
Country [49] 0 0
Sweden
State/province [49] 0 0
Gothenburg
Country [50] 0 0
Sweden
State/province [50] 0 0
Huddinge
Country [51] 0 0
Switzerland
State/province [51] 0 0
Basel
Country [52] 0 0
Switzerland
State/province [52] 0 0
Bern
Country [53] 0 0
Taiwan
State/province [53] 0 0
Changhua County,changhua CITY
Country [54] 0 0
Taiwan
State/province [54] 0 0
Kaohsuing CITY
Country [55] 0 0
Taiwan
State/province [55] 0 0
Taichung City
Country [56] 0 0
Taiwan
State/province [56] 0 0
Tainan City
Country [57] 0 0
Taiwan
State/province [57] 0 0
Taipei City
Country [58] 0 0
Taiwan
State/province [58] 0 0
Taoyuan City
Country [59] 0 0
Turkey
State/province [59] 0 0
Izmir
Country [60] 0 0
Turkey
State/province [60] 0 0
I?stanbul
Country [61] 0 0
Turkey
State/province [61] 0 0
Samsun
Country [62] 0 0
Turkey
State/province [62] 0 0
Sancaktepe
Country [63] 0 0
Ukraine
State/province [63] 0 0
Kyiv
Country [64] 0 0
Ukraine
State/province [64] 0 0
Ternopil
Country [65] 0 0
United Kingdom
State/province [65] 0 0
Liverpool
Country [66] 0 0
United Kingdom
State/province [66] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
UCB Biopharma SRL
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).
Trial website
https://clinicaltrials.gov/study/NCT05063162
Trial related presentations / publications
Mader S, Kumpfel T, Meinl E. Pathomechanisms in demyelination and astrocytopathy: autoantibodies to AQP4, MOG, GFAP, GRP78 and beyond. Curr Opin Neurol. 2022 Jun 1;35(3):427-435. doi: 10.1097/WCO.0000000000001052.
Public notes

Contacts
Principal investigator
Name 0 0
UCB Cares
Address 0 0
001 844 599 2273
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
UCB Cares
Address 0 0
Country 0 0
Phone 0 0
1-844-599-2273 (USA)
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05063162